Discovery and Characterization of MAPK-activated Protein Kinase-2 Prevention of Activation Inhibitors-Reference-Cited by-同舟云学术

Discovery and Characterization of MAPK-activated Protein Kinase-2 Prevention of Activation Inhibitors

Published:2014-10-09 Issue:1 Volume:58 Page:278-293
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Cumming John G.¹,Debreczeni Judit É.¹,Edfeldt Fredrik²,Evertsson Emma²,Harrison Martin¹,Holdgate Geoffrey A.¹,James Michael J.¹,Lamont Scott G.¹,Oldham Keith¹,Sullivan Jane E.¹,Wells Stuart L.¹

Affiliation:

1. AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom

2. AstraZeneca R&D, Pepparedsleden 1, 431 83 Mölndal, Sweden

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm501038s

Reference43 articles.

1. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases

2. The Biology of p38 Kinase: A Central Role in Inflammation

3. The p38α Kinase Plays a Central Role In Inflammation

4. Tocilizumab

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of CC-99677, a selective targeted covalent MAPKAPK2 (MK2) inhibitor for autoimmune disorders;Translational Research;2022-11

2. MAPK-Activated Protein Kinases: Servant or Partner?;Annual Review of Biochemistry;2022-06-21

3. MAP Kinase-Mediated Activation of RSK1 and MK2 Substrate Kinases;Structure;2020-10

4. An Angle on MK2 Inhibition—Optimization and Evaluation of Prevention of Activation Inhibitors;ChemMedChem;2019-08-13

5. Selective inhibition of the p38α MAPK–MK2 axis inhibits inflammatory cues including inflammasome priming signals;Journal of Experimental Medicine;2018-03-16